New UK Drug Applications At ‘Sustained Levels’ Post-Brexit
MHRA Vaunts ‘Exciting’ New Operating Model
Executive Summary
The MHRA’s chief executive explains to the Pink Sheet how the agency will ensure the UK remains an attractive place to seek approval of new innovative drugs and build on the regulatory flexibilities introduced during the COVID-19 pandemic.
You may also be interested in...
UK Clinical Trial Numbers Still ‘Buoyant’ After Brexit
In this second article on the post-Brexit fortunes of the UK medicines regulator, the MHRA, Pink Sheet looks at the emergence of a new UK clinical trials environment, how the agency is facing up to resource pressures, and when the new fee structure might be ready.
UK’s Early Access To Medicines Scheme To Get New Legal Basis
Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.
UK Industry Warns Against Post-Brexit Regulatory Divergence
The UK must maintain a competitive regulatory framework at home, and its medicines agency should play a part in influencing international regulatory policy alongside other national and global organizations, says a new report from the ABPI.